PDS Biotechnology
PDSB
65 hedge funds and large institutions have $47.9M invested in PDS Biotechnology in 2021 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 25 increasing their positions, 11 reducing their positions, and 13 closing their positions.
127% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 11
54% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 13
52% more call options, than puts
Call options by funds: $1.53M | Put options by funds: $1.01M
10% more funds holding
Funds holding: 59 → 65 (+6)
2.96% less ownership
Funds ownership: 23.76% → 20.8% (-3%)
52% less capital invested
Capital invested by funds: $101M → $47.9M (-$52.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
+$1.09M |
| 2 |
Millennium Management
New York
|
+$987K |
| 3 |
Renaissance Technologies
New York
|
+$849K |
| 4 |
First Manhattan
New York
|
+$815K |
| 5 |
SCA
Sassicaia Capital Advisers
Jericho,
New York
|
+$809K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$5.01M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$4.91M |
| 3 |
EI
EAM Investors
Solana Beach,
California
|
-$3.86M |
| 4 |
EGI
EAM Global Investors
Solana Beach,
California
|
-$2.36M |
| 5 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
-$1.15M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
UBS Group
Zurich,
Switzerland
| – | -$44K | -2,946 | Closed |
|
|
AWA
77
Arkadios Wealth Advisors
Atlanta,
Georgia
| – | -$7K | -500 | Closed |
|
78
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
| – | +$463 | +43 | New |
|
PDSB Hedge Fund Activity: Q4 2021 in Review
65 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in PDS Biotechnology (PDSB) for Q4 2021, worth a combined $47.9M — down 52% from $101M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new PDSB positions and 13 closed out — a net gain of 7 holders — while 25 added to existing stakes and 11 trimmed.
The largest buyer was Two Sigma Investments, adding an estimated $1.09M. The largest seller was AIGH Capital Management, cutting an estimated $5.01M.
- 65 institutional investors held PDS Biotechnology (PDSB) as of Q4 2021, up from 59 in Q3 2021.
- Funds reported $47.9M of PDS Biotechnology stock for Q4 2021, down 52% quarter-over-quarter.
- 20 funds opened new PDS Biotechnology positions in Q4 2021 and 13 closed out, a net change of +7 holders.
- The largest PDS Biotechnology buyer in Q4 2021 was Two Sigma Investments, an estimated $1.09M added.
- The largest PDS Biotechnology seller in Q4 2021 was AIGH Capital Management, an estimated $5.01M sold.
Based on aggregated 13F filings for Q4 2021.